Affiliation:
1. Department of Thoracic Oncology, the Third Affiliated Hospital of Xinjiang Medical University, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Abstract
Bone metastasis from lung cancer predicts a decrease in the quality of life and a shortening of survival for patients. While controlling the primary disease, active prevention and treatment of skeletal-related events (SREs) are crucial. The use of bisphosphonates as a basic drug for bone metastases from lung cancer has been increasing; also, the corresponding adverse effects have emerged. The case is here reported of two cases of osteonecrosis of the jaw associated with zoledronic acid treatment were reported in patients with epidermal growth factor receptor -sensitive mutation non-small-cell lung cancer(NSCLC) and discussed the clinical features, early recognition and interventions.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference22 articles.
1. Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2019 Version).;Zhongguo Fei Ai Za Zhi,2019
2. The biology of lung cancer: development of more effective methods for prevention, diagnosis, and treatment.;Salehi-Rad;Clin Chest Med,2020
3. Plasma apolipoprotein E level is associated with the risk of endobronchial biopsy-induced bleeding in patients with lung cancer.;Wang;Lipids Health Dis,2018
4. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: a SEER-based study.;Qiu;Cancer Med,2018
5. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.;Lopez-Olivo;Support Care Cancer,2012
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiple drugs;Reactions Weekly;2023-09-23